argenx SE — FY2018 Form 20-F Summary
Reporting period: Year ended December 31, 2018; this is an annual report, not a standalone Q4 filing. Financial statements are prepared under IFRS as issued by the IASB. Amounts below are in euros unless stated otherwise.
Business context and financial performance
argenx is a clinical-stage biotechnology company developing antibody-based therapies for autoimmune diseases and cancer. It had no approved products and had never generated product-sales revenue; reported revenue came from collaborations, milestones and research services.
| Metric | FY2018 | FY2017 | Change / context |
|---|---|---|---|
| Revenue | €21.5 million | €36.4 million | Down 41%; lower upfront and research-service revenue as collaborative preclinical work concluded |
| Other operating income | €7.7 million | €4.8 million | Up 60%, mainly grants, R&D incentives and payroll tax rebates |
| Research and development expenses | €83.6 million | €51.7 million | Up 62%, reflecting clinical, manufacturing and personnel costs |
| Selling, general and administrative expenses | €27.5 million | €12.4 million | Up 121%, including hiring, share-based compensation and commercialization preparation |
| Operating loss | €81.8 million | €22.9 million | Loss widened substantially |
| Net loss | €66.6 million | €28.1 million | Basic and diluted loss per share: €1.99, versus €1.14 |
| Operating cash flow | €53.8 million used | €36.5 million used | Higher cash use reflected increased development spending |
Financial income was €3.7 million. A €12.3 million foreign-exchange gain, primarily unrealized gains on U.S.-dollar balances, partly offset the operating loss. No meaningful product gross margin is reported because the company had no product sales.
Liquidity, capital and obligations
- At year-end, cash and cash equivalents were €281.0 million and current financial assets were €283.5 million; combined cash, cash equivalents and current financial assets totaled €564.6 million.
- Total assets were €578.5 million, total liabilities €40.1 million and equity €538.4 million. The filing reports no material financing commitments such as credit lines and no borrowings in the presented balance-sheet figures.
- Financing cash inflow was €244.7 million, principally net proceeds of €241.1 million from the September 2018 U.S. offering. Investing cash outflow of €107.5 million largely reflected purchases of current financial assets; capital expenditures were €0.7 million.
- Management stated that year-end resources were expected to fund operating expenses and capital requirements for at least the next 12 months. Contractual obligations included €3.0 million in operating leases and €46.6 million in purchase obligations, chiefly manufacturing commitments.
- At December 31, 2018, 35,975,312 ordinary shares were outstanding. Accumulated losses were €169.6 million.
Material changes, outlook and notable items
- Development advanced for efgartigimod: the first Phase 3 trial in myasthenia gravis (MG) began in September 2018; Phase 2 studies in immune thrombocytopenia (ITP) and pemphigus vulgaris (PV) reported results, and a subcutaneous formulation showed comparable key measures to intravenous dosing in a Phase 1 study. Management planned further work in ITP, PV and chronic inflammatory demyelinating polyneuropathy (CIDP) during 2019, subject to trial and regulatory progress.
- Cusatuzumab, studied with azacytidine in AML/high-risk MDS, showed a reported 92% response rate among treated newly diagnosed AML patients in interim Phase 1 data. Its development carries clinical, safety and execution risks.
- In December 2018, argenx agreed to collaborate with Janssen on cusatuzumab. After year-end, argenx received a $300 million upfront payment and JJDC invested €176.7 million for newly issued shares; the agreement also provides potential milestone payments of up to $1.3 billion and royalties. These are post-period developments, not FY2018 operating revenue or year-end cash.
- Other post-period items included a February 2019 Halozyme ENHANZE license, involving a $30 million upfront payment and potential milestone and royalty obligations, and a March 2019 $30 million AbbVie milestone following clinical development initiation for ABBV-151.
- The company expected continued substantial losses and rising R&D costs. It has no approved products, depends on successful trials and regulatory approvals, and may need additional funding as programs progress. Management said there were no off-balance-sheet arrangements and no current material legal proceedings.
- Currency movements are material: the company has U.S.-dollar receipts and investments, reports in euros and had no foreign-exchange hedging arrangements. A 10% USD/EUR movement would have changed the year-end value of exposed monetary assets by about €28.4 million, according to the filing.
- IFRS 15 was adopted in 2018, with a €2.4 million reduction to opening accumulated equity. Reported 2018 revenue and loss reflect the new revenue-recognition policy.
Controls, audit and principal risks
The financial-statement audit opinion was unqualified, but the auditor issued an adverse opinion on internal control over financial reporting. Management and the auditor identified material weaknesses involving risk assessment, control activities, information and communication, monitoring, IT general controls, and financial closing and reporting processes. Disclosure controls were deemed ineffective at year-end. Management began remediation, including hiring an internal controls manager and strengthening system access reviews, but did not assure that remediation would be timely or effective.
Key business risks include clinical-trial failure or delay, adverse effects, regulatory uncertainty, dependence on third-party manufacturers and collaborators, competition, intellectual-property challenges, reimbursement and pricing pressure, and the need for future financing. The filing also notes uncertainty around tax incentives and a pending Belgian tax ruling connected with the 2017 restructuring.
Most important facts for investors to verify
- Whether the material internal-control weaknesses are remediated and whether subsequent filings report effective controls.
- Clinical-trial progress, full and final data, safety findings and regulatory plans for efgartigimod and cusatuzumab.
- How the Janssen collaboration’s cost-sharing, development governance, milestones and royalties translate into cash flows and future obligations.
- Cash burn, investment liquidity and committed manufacturing spending against the company’s stated runway.
- Outcome of the Belgian tax ruling and continued eligibility for grants, R&D incentives and payroll tax rebates.